Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilli.

[1]  R. Jones,et al.  Antimicrobial activity of amikacin combinations against Enterobacteriaceae moderately susceptible to third-generation cephalosporins , 1982, Antimicrobial Agents and Chemotherapy.

[2]  K. Bush,et al.  Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria , 1982, Antimicrobial Agents and Chemotherapy.

[3]  H. Giamarellou,et al.  In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa , 1984, Antimicrobial Agents and Chemotherapy.

[4]  J. Jorgensen,et al.  In vitro activity of aztreonam in combination with newer beta-lactams and amikacin against multiply resistant gram-negative bacilli , 1984, Antimicrobial Agents and Chemotherapy.

[5]  L. Elting,et al.  Aztreonam therapy in neutropenic patients with cancer. , 1986, The American journal of medicine.

[6]  J. Bosso,et al.  In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis , 1987, Antimicrobial Agents and Chemotherapy.

[7]  J. Wade,et al.  In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa , 1990, Antimicrobial Agents and Chemotherapy.

[8]  J. Bosso,et al.  In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis , 1990, Antimicrobial Agents and Chemotherapy.

[9]  J. Baldwin,et al.  Gamma-lactam analogues of beta-lactam antibiotics. , 1991, The Journal of antibiotics.

[10]  R. Jones,et al.  Antimicrobial activity of isepamicin (SCH21420, 1-N-HAPA gentamicin B) combinations with cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem, mezlocillin and piperacillin tested against gentamicin-resistant and susceptible gram-negative bacilli and enterococci. , 1991, Journal of chemotherapy.

[11]  H. Uchida,et al.  Synergy with aztreonam and arbekacin or tobramycin against Pseudomonas aeruginosa isolated from blood. , 1992, The Journal of antimicrobial chemotherapy.

[12]  J. Washington,et al.  Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli. , 1996, Diagnostic microbiology and infectious disease.

[13]  R. Jones,et al.  In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains. , 1996, Journal of chemotherapy.

[14]  K. Bowker,et al.  In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics. , 1999, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[15]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[16]  R. Jung,et al.  In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa. , 2002, Diagnostic microbiology and infectious disease.

[17]  Wonkeun Song,et al.  In vitro activity of β-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa , 2003 .

[18]  C. Nightingale,et al.  An approach for the evaluation of synergy between antimicrobials. , 2003, International journal of antimicrobial agents.